Companies / Canada
BMS Launches Arthritis Drug
September 2006 | Product LaunchBoosting the value of the country's prescription drug sector, US firm Bristol-Myers Squibb (BMS) has launched its biologic rheumatoid arthritis (RA) product Orencia (abatacept) in Canada. The agent has been available in the US since February and is expected to attain worldwide blockbuster status before
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
